デフォルト表紙
市場調査レポート
商品コード
1107132

性器ヘルペス治療市場 - 世界の見通しと予測(2022年~2027年)

Genital Herpes Treatment Market - Global Outlook and Forecast 2022-2027

出版日: | 発行: Arizton Advisory & Intelligence | ページ情報: 英文 298 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=134.29円
性器ヘルペス治療市場 - 世界の見通しと予測(2022年~2027年)
出版日: 2022年07月27日
発行: Arizton Advisory & Intelligence
ページ情報: 英文 298 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の性器ヘルペス治療の市場規模は、予測期間の2022年~2028年に3.76%のCAGRで拡大すると予測されています。

当レポートでは、世界の性器ヘルペス治療市場について調査し、市場の概要とともに、薬剤タイプ別、流通チャネル別、ウイルスタイプ別、投与経路別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 調査手法

第2章 調査目的

第3章 調査プロセス

第4章 範囲と適用範囲

第5章 レポートの前提と注意事項

第6章 市場概要

第7章 イントロダクション

第8章 市場機会と動向

  • 性器ヘルペスワクチン候補の研究開発
  • LGBTQ+コミュニティにおける性器ヘルペス症例の増加
  • 低中所得国における市場成長の可能性
  • 性器ヘルペス治療薬のオンライン購入の増加

第9章 市場の成長促進要因

第10章 市場の成長要因

第11章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第12章 薬剤タイプ

  • 市場概要および成長促進要因
  • 市場概要
  • アシクロビル
  • バラシクロビル
  • ファムシクロビル
  • その他

第13章 流通経路

  • 市場概要および成長促進要因
  • 市場概要
  • 小売薬局
  • 院内薬局
  • オンライン薬局

第14章 ウイルスタイプ

  • 市場概要および成長促進要因
  • 市場概要
  • HSV-2
  • HSV-1

第15章 投与経路

  • 市場概要および成長促進要因
  • 市場概要
  • 経口
  • 局所
  • 注射

第16章 地域

第17章 北米

第18章 欧州

第19章 アジア太平洋

第20章 ラテンアメリカ

第21章 中東・アフリカ

第22章 競合情勢

第23章 主要企業のプロファイル

  • GLAXOSMITHKLINE
  • GLENMARK PHARMACEUTICALS
  • VIATRIS
  • NOVARTIS AG
  • TEVA PHARMACEUTICALS
  • BAUSCH HEALTH COMPANIES INC.

第24章 その他の著名なベンダー

  • AVET PHARMACEUTICALS
  • AUROBINDO PHARMA
  • ABBOTT
  • ADLEY FORMULATIONS
  • CENTURION REMEDIES
  • CIPLA
  • DR. REDDY'S LABORATORIES
  • ELI LILLY AND COMPANY
  • FDC LIMITED
  • FINECURE PHARMACEUTICALS LIMITED
  • HETERO
  • MACLEODS PHARMACEUTICALS
  • MEDICO REMEDIES LIMITED
  • PFIZER INC.
  • TORRENT PHARMA
  • ZEELAB PHARMACY
  • ZYDUS GROUP

第25章 レポートの概要

第26章 定量的要約

第27章 付録

図表

LIST OF EXHIBITS

  • EXHIBIT 1 GLOBAL GENITAL HERPES TREATMENT MARKET SEGMENTATION
  • EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2021
  • EXHIBIT 3 GLOBAL PREVALENCE OF HSV INFECTIONS 2016
  • EXHIBIT 4 IMPACT OF R&D OF GENITAL HERPES VACCINE CANDIDATES
  • EXHIBIT 5 IMPACT OF RISE IN GENITAL HERPES CASES IN LGBTQ+ COMMUNITY
  • EXHIBIT 6 IMPACT OF MARKET GROWTH POTENTIAL IN LOW-MIDDLE-INCOME COUNTRIES
  • EXHIBIT 7 IMPACT OF INCREASED ONLINE PURCHASE OF GENITAL HERPES THERAPEUTICS
  • EXHIBIT 8 IMPACT OF INCREASED BURDEN OF STDS
  • EXHIBIT 9 HSV-2 INFECTION BY SEX (MILLION)
  • EXHIBIT 10 IMPACT OF AWARENESS OF STIS
  • EXHIBIT 11 IMPACT OF DEMAND FOR TOPICAL GENITAL HERPES TREATMENT DRUGS
  • EXHIBIT 12 ADVANTAGES OF TOPICAL DRUG FORMULATIONS
  • EXHIBIT 13 IMPACT OF SOCIAL STIGMA ASSOCIATED WITH STDS
  • EXHIBIT 14 IMPACT OF SIDE EFFECTS & ADVERSE REACTIONS TO GENITAL HERPES MEDICATIONS
  • EXHIBIT 15 COMMON SIDE EFFECTS OF GENITAL HERPES MEDICATIONS
  • EXHIBIT 16 SEVERE SIDE EFFECTS OF GENITAL HERPES MEDICATIONS
  • EXHIBIT 17 IMPACT OF LIMITATIONS OF GENITAL HERPES TREATMENT MEDICATIONS
  • EXHIBIT 18 GLOBAL GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 19 FIVE FORCES ANALYSIS 2021
  • EXHIBIT 20 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
  • EXHIBIT 21 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE: INCREMENTAL GROWTH
  • EXHIBIT 22 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE: ABSOLUTE GROWTH
  • EXHIBIT 23 GLOBAL GENITAL HERPES TREATMENT MARKET BY ACYCLOVIR: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 24 GLOBAL GENITAL HERPES TREATMENT MARKET BY ACYCLOVIR 2021-2027 ($ MILLION)
  • EXHIBIT 25 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 26 GLOBAL GENITAL HERPES TREATMENT MARKET BY VALACYCLOVIR: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 27 GLOBAL GENITAL HERPES TREATMENT MARKET BY VALACYCLOVIR 2021-2027 ($ MILLION)
  • EXHIBIT 28 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 29 GLOBAL GENITAL HERPES TREATMENT MARKET BY FAMCICLOVIR: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 30 GLOBAL GENITAL HERPES TREATMENT MARKET BY FAMCICLOVIR 2021-2027 ($ MILLION)
  • EXHIBIT 31 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 32 GLOBAL GENITAL HERPES TREATMENT MARKET BY OTHER DRUGS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 33 GLOBAL GENITAL HERPES TREATMENT MARKET BY OTHER DRUGS 2021-2027 ($ MILLION)
  • EXHIBIT 34 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 35 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
  • EXHIBIT 36 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL: INCREMENTAL GROWTH
  • EXHIBIT 37 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL: ABSOLUTE GROWTH
  • EXHIBIT 38 GLOBAL GENITAL HERPES TREATMENT MARKET BY RETAIL PHARMACIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 39 GLOBAL GENITAL HERPES TREATMENT MARKET BY RETAIL PHARMACIES 2021-2027 ($ MILLION)
  • EXHIBIT 40 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 41 GLOBAL GENITAL HERPES TREATMENT MARKET BY HOSPITAL PHARMACIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 42 GLOBAL GENITAL HERPES TREATMENT MARKET BY HOSPITAL PHARMACIES 2021-2027 ($ MILLION)
  • EXHIBIT 43 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 44 GLOBAL GENITAL HERPES TREATMENT MARKET BY ONLINE PHARMACIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 45 GLOBAL GENITAL HERPES TREATMENT MARKET BY ONLINE PHARMACIES 2021-2027 ($ MILLION)
  • EXHIBIT 46 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 47 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
  • EXHIBIT 48 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE: INCREMENTAL GROWTH
  • EXHIBIT 49 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE: ABSOLUTE GROWTH
  • EXHIBIT 50 GLOBAL PREVALENCE OF HSV-1 AND HSV-2 2016 (BILLION)
  • EXHIBIT 51 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-2: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 52 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-2 2021-2027 ($ MILLION)
  • EXHIBIT 53 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 54 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-1: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 55 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-1 2021-2027 ($ MILLION)
  • EXHIBIT 56 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 57 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 58 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION: INCREMENTAL GROWTH
  • EXHIBIT 59 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION: ABSOLUTE GROWTH
  • EXHIBIT 60 GLOBAL ORAL GENITAL HERPES TREATMENT MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 61 GLOBAL ORAL GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 62 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 63 GLOBAL TOPICAL GENITAL HERPES TREATMENT MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 64 GLOBAL TOPICAL GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 65 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 66 GLOBAL INJECTION GENITAL HERPES TREATMENT MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
  • EXHIBIT 67 GLOBAL INJECTION GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 68 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 69 INCREMENTAL GROWTH BY GEOGRAPHY 2021 & 2027
  • EXHIBIT 70 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY
  • EXHIBIT 71 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 72 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
  • EXHIBIT 73 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
  • EXHIBIT 74 NORTH AMERICA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 75 NORTH AMERICA GENITAL HERPES TREATMENT MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 76 GENITAL HERPES TREATMENT MARKET IN NORTH AMERICA 2021-2027 ($ MILLION)
  • EXHIBIT 77 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
  • EXHIBIT 78 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
  • EXHIBIT 79 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
  • EXHIBIT 80 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 81 INCREMENTAL GROWTH IN NORTH AMERICA 2021 & 2027
  • EXHIBIT 82 PREVALENCE & INCIDENCE OF STIS IN US
  • EXHIBIT 83 US GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 84 CANADA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 85 EUROPE GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 86 EUROPE GENITAL HERPES TREATMENT MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 87 EUROPE GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 88 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
  • EXHIBIT 89 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
  • EXHIBIT 90 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
  • EXHIBIT 91 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 92 INCREMENTAL GROWTH IN EUROPE 2021 & 2027
  • EXHIBIT 93 GERMANY GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 94 FRANCE GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 95 UK GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 96 ITALY GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 97 SPAIN GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 98 APAC GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 99 APAC GENITAL HERPES TREATMENT MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 100 APAC GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 101 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
  • EXHIBIT 102 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
  • EXHIBIT 103 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
  • EXHIBIT 104 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 105 INCREMENTAL GROWTH IN APAC 2021 & 2027
  • EXHIBIT 106 CHINA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 107 JAPAN GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 108 INDIA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 109 SOUTH KOREA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 110 PRIORITY POPULATIONS FOR FOURTH NATIONAL STI STRATEGY 2018-2022 AUSTRALIA
  • EXHIBIT 111 AUSTRALIA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 112 LATIN AMERICA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 113 LATIN AMERICA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 114 LATIN AMERICA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 115 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
  • EXHIBIT 116 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
  • EXHIBIT 117 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
  • EXHIBIT 118 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 119 INCREMENTAL GROWTH IN LATIN AMERICA 2021 & 2027
  • EXHIBIT 120 BRAZIL GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 121 MEXICO GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 122 ARGENTINA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 123 MEA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 124 MEA GENITAL HERPES TREATMENT MARKET: KEY COUNTRIES ($ MILLION)
  • EXHIBIT 125 MEA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 126 INCREMENTAL GROWTH BY DRUG TYPE 2021 & 2027
  • EXHIBIT 127 INCREMENTAL GROWTH BY DISTRIBUTION CHANNEL 2021 & 2027
  • EXHIBIT 128 INCREMENTAL GROWTH BY VIRUS TYPE 2021 & 2027
  • EXHIBIT 129 INCREMENTAL GROWTH BY ROUTE OF ADMINISTRATION 2021 & 2027
  • EXHIBIT 130 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2021 & 2027
  • EXHIBIT 131 SOUTH AFRICA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 132 TURKEY GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 133 SAUDI ARABIA GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • EXHIBIT 134 GLAXOSMITHKLINE: TOTAL REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 135 GLAXOSMITHKLINE: R&D EXPENDITURE 2018-2020 ($ BILLION)
  • EXHIBIT 136 GLAXOSMITHKLINE: REVENUE BY BUSINESS SEGMENT 2018-2020 ($ BILLION)
  • EXHIBIT 137 GLAXOSMITHKLINE: REVENUE SHARE BY GEOGRAPHY 2018-2020 ($ BILLION)
  • EXHIBIT 138 GLENMARK PHARMACEUTICALS: TOTAL REVENUE 2019-2021 ($ MILLION)
  • EXHIBIT 139 GLENMARK PHARMACEUTICALS: R&D EXPENSE 2019-2021 ($ MILLION)
  • EXHIBIT 140 GLENMARK PHARMACEUTICALS: REVENUE SHARE BY GEOGRAPHY 2021 (%)
  • EXHIBIT 141 VIATRIS: TOTAL REVENUE 2019-2021 ($ BILLION)
  • EXHIBIT 142 VIATRIS: R&D EXPENDITURE 2019-2021 ($ MILLION)
  • EXHIBIT 143 VIATRIS: REVENUE SHARE BY GEOGRAPHY 2021 (%)
  • EXHIBIT 144 NOVARTIS AG: TOTAL REVENUE 2018-2020 ($ BILLION)
  • EXHIBIT 145 NOVARTIS AG: REVENUE BY BUSINESS DIVISION 2018-2020 ($ BILLION)
  • EXHIBIT 146 NOVARTIS AG: R&D EXPENDITURE 2018-2020 ($ BILLION)
  • EXHIBIT 147 TEVA PHARMACEUTICALS: TOTAL REVENUE 2019-2021 ($ BILLION)
  • EXHIBIT 148 TEVA PHARMACEUTICALS: R&D EXPENDITURE 2019-2021 ($ MILLION)
  • EXHIBIT 149 TEVA PHARMACEUTICALS: REVENUE SHARE BY BUSINESS SEGMENT 2021 (%)
  • EXHIBIT 150 BAUSCH HEALTH COMPANIES INC.: TOTAL REVENUE 2019-2020 ($ BILLION)
  • EXHIBIT 151 BAUSCH HEALTH COMPANIES INC.: R&D EXPENDITURE 2018-2020 ($ MILLION)
  • EXHIBIT 152 BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY BUSINESS SEGMENT 2021 (%)

LIST OF TABLES

  • TABLE 1 KEY CAVEATS
  • TABLE 2 CURRENCY CONVERSION 2015-2021
  • TABLE 3 HERPES VACCINE PIPELINE CANDIDATES
  • TABLE 4 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE
  • TABLE 5 FAMCICLOVIR PRICING DETAILS
  • TABLE 6 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL
  • TABLE 7 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE
  • TABLE 8 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION
  • TABLE 9 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 10 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 11 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 12 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 13 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 14 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 15 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 16 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 17 AMERICANS' SELF-IDENTIFIED SEXUAL ORIENTATION
  • TABLE 18 EUROPE GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 19 EUROPE GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 20 EUROPE GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 21 EUROPE GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 22 EUROPE GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 23 EUROPE GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 24 EUROPE GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 25 EUROPE GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 26 APAC GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 27 APAC GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 28 APAC GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 29 APAC GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 30 APAC GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 31 APAC GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 32 APAC GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 33 APAC GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 34 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 35 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 36 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 37 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 38 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 39 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 40 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 41 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 42 MEA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 43 MEA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 44 MEA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 45 MEA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 46 MEA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 47 MEA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 48 MEA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 49 MEA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 50 GLAXOSMITHKLINE: MAJOR PRODUCT OFFERINGS
  • TABLE 51 GLENMARK PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 52 VIATRIS: MAJOR PRODUCT OFFERINGS
  • TABLE 53 NOVARTIS AG: MAJOR PRODUCT OFFERINGS
  • TABLE 54 TEVA PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 55 BAUSCH HEALTH COMPANIES INC.: MAJOR PRODUCT OFFERINGS
  • TABLE 56 AVET PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 57 AUROBINDO PHARMA: MAJOR PRODUCT OFFERINGS
  • TABLE 58 ABBOTT: MAJOR PRODUCT OFFERINGS
  • TABLE 59 ADLEY FORMULATIONS: MAJOR PRODUCT OFFERINGS
  • TABLE 60 CENTURION REMEDIES: MAJOR PRODUCT OFFERINGS
  • TABLE 61 CIPLA: MAJOR PRODUCT OFFERINGS
  • TABLE 62 DR. REDDY'S LABORATORIES: MAJOR PRODUCT OFFERINGS
  • TABLE 63 ELI LILLY AND COMPANY: MAJOR PRODUCT OFFERINGS
  • TABLE 64 FDC LIMITED: MAJOR PRODUCT OFFERINGS
  • TABLE 65 FINECURE PHARMACEUTICALS LIMITED: MAJOR PRODUCT OFFERINGS
  • TABLE 66 HETERO: MAJOR PRODUCT OFFERINGS
  • TABLE 67 MACLEODS PHARMACEUTICALS: MAJOR PRODUCT OFFERINGS
  • TABLE 68 MEDICO REMEDIES LIMITED: MAJOR PRODUCT OFFERINGS
  • TABLE 69 PFIZER INC.: MAJOR PRODUCT OFFERINGS
  • TABLE 70 TORRENT PHARMA: MAJOR PRODUCT OFFERINGS
  • TABLE 71 ZEELAB PHARMACY: MAJOR PRODUCT OFFERINGS
  • TABLE 72 ZYDUS GROUP: MAJOR PRODUCT OFFERINGS
  • TABLE 73 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 74 GLOBAL GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 75 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 76 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 77 EUROPE GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 78 EUROPE GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 79 APAC GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 80 APAC GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 81 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 82 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 83 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 ($ MILLION)
  • TABLE 84 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY DRUG TYPE 2021-2027 (%)
  • TABLE 85 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 86 GLOBAL GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 87 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 88 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 89 EUROPE GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 90 EUROPE GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 91 APAC GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 92 APAC GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 93 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 94 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 95 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 ($ MILLION)
  • TABLE 96 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY DISTRIBUTION CHANNEL 2021-2027 (%)
  • TABLE 97 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 98 GLOBAL GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 99 NORTH AMERICA HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 100 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 101 EUROPE GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 102 EUROPE GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 103 APAC GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 104 APAC GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 105 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 106 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 107 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 ($ MILLION)
  • TABLE 108 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY VIRUS TYPE 2021-2027 (%)
  • TABLE 109 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 110 GLOBAL GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 111 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 112 NORTH AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 113 EUROPE GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 114 EUROPE GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021202-7 (%)
  • TABLE 115 APAC GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 116 APAC GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 117 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 118 LATIN AMERICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 119 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 ($ MILLION)
  • TABLE 120 MIDDLE EAST & AFRICA GENITAL HERPES TREATMENT MARKET BY ROUTE OF ADMINISTRATION 2021-2027 (%)
  • TABLE 121 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY 2021-2027 ($ MILLION)
  • TABLE 122 GLOBAL GENITAL HERPES TREATMENT MARKET BY GEOGRAPHY 2021-2027 (%)
  • TABLE 123 GLOBAL GENITAL HERPES TREATMENT MARKET BY ACYCLOVIR 2021-2027 ($ MILLION)
  • TABLE 124 GLOBAL GENITAL HERPES TREATMENT MARKET BY ACYCLOVIR 2021-2027 (%)
  • TABLE 125 GLOBAL GENITAL HERPES TREATMENT MARKET BY VALACYCLOVIR 2021-2027 ($ MILLION)
  • TABLE 126 GLOBAL GENITAL HERPES TREATMENT MARKET BY VALACYCLOVIR 2021-2027 (%)
  • TABLE 127 GLOBAL GENITAL HERPES TREATMENT MARKET BY FAMCICLOVIR 2021-2027 ($ MILLION)
  • TABLE 128 GLOBAL GENITAL HERPES TREATMENT MARKET BY FAMCICLOVIR 2021-2027 (%)
  • TABLE 129 GLOBAL GENITAL HERPES TREATMENT MARKET BY OTHER DRUGS 2021-2027 ($ MILLION)
  • TABLE 130 GLOBAL GENITAL HERPES TREATMENT MARKET BY OTHER DRUGS 2021-2027 (%)
  • TABLE 131 GLOBAL GENITAL HERPES TREATMENT MARKET BY RETAIL PHARMACIES 2021-2027 ($ MILLION)
  • TABLE 132 GLOBAL GENITAL HERPES TREATMENT MARKET BY RETAIL PHARMACIES 2021-2027 (%)
  • TABLE 133 GLOBAL GENITAL HERPES TREATMENT MARKET BY HOSPITAL PHARMACIES 2021-2027 ($ MILLION)
  • TABLE 134 GLOBAL GENITAL HERPES TREATMENT MARKET BY HOSPITAL PHARMACIES 2021-2027 (%)
  • TABLE 135 GLOBAL GENITAL HERPES TREATMENT MARKET BY ONLINE PHARMACIES 2021-2027 ($ MILLION)
  • TABLE 136 GLOBAL GENITAL HERPES TREATMENT MARKET BY ONLINE PHARMACIES 2021-2027 (%)
  • TABLE 137 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-2 2021-2027 ($ MILLION)
  • TABLE 138 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-2 2021-2027 (%)
  • TABLE 139 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-1 2021-2027 ($ MILLION)
  • TABLE 140 GLOBAL GENITAL HERPES TREATMENT MARKET BY HSV-1 2021-2027 (%)
  • TABLE 141 GLOBAL ORAL GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • TABLE 142 GLOBAL ORAL GENITAL HERPES TREATMENT MARKET 2021-2027 (%)
  • TABLE 143 GLOBAL TOPICAL GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • TABLE 144 GLOBAL TOPICAL GENITAL HERPES TREATMENT MARKET 2021-2027 (%)
  • TABLE 145 GLOBAL INJECTION GENITAL HERPES TREATMENT MARKET 2021-2027 ($ MILLION)
  • TABLE 146 GLOBAL INJECTION GENITAL HERPES TREATMENT MARKET 2021-2027 (%)
目次
Product Code: ARZ220517

The global genital herpes treatment market is expected to grow at a CAGR of 3.76% during 2022-2028

Herpes simplex virus (HSV), also known as herpes, is a widespread infection worldwide. HSV-1 causes infection in or around the mouth (oral herpes), but it can also cause genital herpes. Herpes simplex virus type 2 (HSV-2) causes genital herpes, a dangerous sexually transmitted infection (STI). The genitals of those who have genital herpes develop painful blisters. Blisters can form on the anus or inside it. Oral and vaginal herpes is usually asymptomatic or unnoticed, but they can cause painful blisters or ulcers at the injection site, ranging from mild to severe. The infection is permanent, and symptoms might repeat for years.

The World Health Organization estimates that 20% of people living with HIV / AIDS are in their 20s and that 1 in 20 adolescents get STI each year. Adolescents are more likely to engage in unprotected sex, have multiple sexual partners, and engage in transgenerational transactional sex. The cervical lining in female adults and young women makes them more susceptible to STIs. According to the CDC, roughly 20% of the U.S. population - approximately one out of every five people in the U.S. had an STI on any given day in 2018; October 13 is National Herpes Awareness Day, an excellent opportunity to raise awareness about the causes and treatment of various types of herpes contaminations, particularly genital herpes. The disease and treatment searches are increasing with the high internet penetration around the globe. Young adults are giving more time to internet browsing. They frequently search about the treatment methods for STIs and their prevention. MSM are vulnerable demographics to spreading STIs. While anyone who has sex can get an STD, the sexually active LGBT population, including gay, bisexual, and MSM, are at greater risk. In addition to getting higher rates of HSV, more than half of all new HIV infections happen among MSM. Many aspects contribute to the higher rates of STIs among LGBT.

Promising Investigational Therapies for Treating Genital Herpes

  • Researchers have been working on the development of herpes vaccines for decades. Several clinical trials have been conducted to test therapeutic (to reduce recurrence and viral shedding in people already infected with HSV) and prophylactic (to prevent infection) drug candidates.
  • mRNA-1608 a Moderna's HSV vaccine candidate is a vaccine candidate against HSV-2 infection. Moderna believes that an HSV-2 vaccine could provide cross-protection against HSV-1. With mRNA-1608, the Company intends to bring a strong antibody reaction with neutralizing and effector functionality shared with cell-mediated immunity.
  • HSV 2 Vaccines, RVx-201, NE HSV-2 Vaccine, HDIT 101, Pritelivir, UB-621, and other critical Genital Herpes pipeline medicines are in various stages of clinical trials for the treatment of Genital Herpes.
  • Sanofi, Rational Vaccines, BlueWillow Biologics, Heidelberg ImmunoTherapeutics, AiCuris, and United Biopharma are some of the most well-known pharmaceutical companies active in the field.
  • X-Vax Technology announced in May 2021 that it is preparing to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its experimental herpes simplex virus 1 and 2 vaccines (HSV-1 and -2).
  • The FDA granted AiCuris Breakthrough Therapy Designation for Pritelivir to treat HSV infections in immunocompromised patients in June 2020.

Increasing Demand for Genital Herpes Treatment by Homosexuals

  • Homosexual acceptance increased by double digits between 2002 and 2019. This includes a 21-point increase in South Africa since 2002 and a 19-point increase in South Korea over the same period. India has also seen a rise of 22 points since 2014.
  • MSM groups are at increased risk of HIV and other STIs due to sexual networks, the number of concurrent partners, and behavioral or biological factors such as condom-less sex, anal sex, drug use, etc.
  • MSM are vulnerable demographics to spreading STIs. While anyone having sex can get an STD, the sexually active LGBT population, including gay, bisexual, and MSM, are at greater risk.
  • In addition to getting higher rates of HSV, more than half of all new HIV infections happen among MSM. Many aspects contribute to the higher rates of STIs among MSM.

Growing Burden of Sexually Transmitted Diseases

  • As the latest data from WHO, an expected 3.7 billion individuals younger than 50, or 67% of the populace, in 2016 had HSV-1 contamination (oral or genital). The assessed predominance of the contamination was most elevated in Africa (88%) and least in the Americas (45%).
  • Genital herpes caused by HSV-2 is a global problem. According to WHO data published in 2022, an estimated 491 million (13%) aged 15-49 years suffered from infections worldwide in 2016. More women than men are infected with HSV-2. In 2016, an estimated 313 million women and 178 million men lived with the infection. This is because male-to-female sexually transmitted HSV is more efficient than female-to-male sexual transmission.
  • Genital herpes is a worldwide issue, and an expected 491 million (around 13%) individuals between 15 and 49 years suffer from this STD. In 2016, around 313 million women and 178 million men had genital herpes. This is because sexual transmission of HSV is more proficient from men to ladies than from ladies to men. The pervasiveness of HSV-2 disease was assessed to be most noteworthy in Africa (44% in ladies and 25% in men), trailed by the Americas (24% in ladies and 12% in men). 

MARKET SEGMENTATION ANALYSIS

The global genital herpes treatment market is segmented based on drug type, distribution channel, virus type, route of administration, and geography.

The Acyclovir segment reported a significant share of around 50.44% among all drug types. The Acyclovir is the leading segment due to availability in all three major routes of administration. The key player in the genital herpes treatment GSK has the branded drug Zovirax. Acyclovir is the oldest drug in the antiviral category and has many generic versions of Zovirax available on the market.

The Retail pharmacies segment reported a significant share of around 49.79% among all distribution channels. The retail pharmacy segment is showing the highest share due to the availability of branded and generic versions of all antiviral drugs in retail pharmacies. People who have genital herpes is most referred to go to nearby retail pharmacy outlet for anti-genital herpes treatment because of the stigma related to sexually transmitted diseases.

The HSV-2 segment reported a major share of around 84.10% among all virus types. HSV-2 is the leading virus type segment as HSV-2 is the leading cause of genital herpes. According to WHO data published in 2022, an estimated 491 million (13%) aged 15-49 years were suffering from infections worldwide in 2016. More women than men are infected with HSV-2.

Among all routes of administration, the oral segment reported a major share of around 64.03%. Mostly all the anti-genital herpes drugs are available in an oral formulation. Chronic suppressive doses of oral antivirals, including Acyclovir (Zovirax), valacyclovir (Valtrex), and famciclovir, have significantly reduced the incidence of clinical recurrence and the rate of asymptomatic excretion. Oral administration of Acyclovir effectively suppresses recurrent genital herpes. Daily administration of Acyclovir reduces the recurrence rate by up to 80%, and 25-30% of patients have no further recurrence while taking the drug.

Segmentation by Drug Type

  • Acyclovir
  • Valacyclovir
  • Famciclovir
  • Other Drugs

Segmentation by Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Segmentation by Virus Type

  • HSV-2
  • HSV-1

Segmentation by Route of Administration:

  • Oral
  • Topical
  • Injection

GEOGRAPHIC ANALYSIS

North America is the major revenue contributor to the global genital herpes treatment market, with a share of more than 40%. In North America, the US is the key revenue contributor mainly due to an increase in the demand for genital herpes drugs reflecting the growing awareness of various antiviral drugs and their benefits against different STIs, including genital herpes. Europe is the second-largest regional market and is witnessing steady growth owing to increasing acceptance of both branded and OTC antiviral drugs for treating genital herpes. However, APAC is likely to see faster growth than all other regions. Around 1 in every ten people in APAC are infected with HSV-2, which majorly causes genital herpes. The APAC region is witnessing high demand for off-label, generic, and OTC drugs for treating genital herpes. The region has many regional and local vendors offering generic and OTC antiviral drugs, which are majorly used for treating genital herpes.

Segmentation by Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Turkey
    • Saudi Arabia

Key Vendors

  • GlaxoSmithKline
  • Glenmark pharmaceuticals
  • Viatris
  • Novartis
  • Teva Pharmaceuticals
  • Bausch Health Companies

Other Prominent Vendors

  • Reddy's Laboratories
  • Cipla
  • Pfizer
  • Eli Lilly & Company
  • Avet Pharmaceuticals
  • Aurobindo Pharma
  • Centurion Remedies
  • Abbott
  • Macleods Pharmaceuticals
  • FDC
  • Hetero
  • Zydus Group
  • Torrent Pharma
  • Finecure Pharmaceuticals
  • ADLEY FORMULATIONS
  • Medico Remedies
  • Zeelab Pharmacy

KEY QUESTIONS ANSWERED

  • 1. HOW BIG IS THE GLOBAL GENITAL HERPES TREATMENT MARKET?
  • 2. WHAT IS THE GROWTH RATE OF THE GLOBAL GENITAL HERPES TREATMENT MARKET?
  • 3. WHO ARE THE KEY PLAYERS IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
  • 4. WHAT ARE THE LATEST TRENDS & OPPORTUNITIES IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?
  • 5. WHICH REGION HOLDS THE LARGEST SHARE IN THE GLOBAL GENITAL HERPES TREATMENT MARKET?

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
    • 4.3.1 MARKET SEGMENTATION BY DRUG TYPE
    • 4.3.2 MARKET SEGMENTATION BY DISTRIBUTION CHANNEL
    • 4.3.3 MARKET SEGMENTATION BY VIRUS TYPE
    • 4.3.4 MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION
    • 4.3.5 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 MARKET AT A GLANCE

7 INTRODUCTION

  • 7.1 OVERVIEW
    • 7.1.1 STI CONTROL HEALTH POLICY AGENDA
    • 7.1.2 GLOBAL PREVALENCE OF HSV INFECTIONS
    • 7.1.3 RISK OF HIV AND GENITAL HERPES AMONG THE LGBTQ+ COMMUNITY

8 MARKET OPPORTUNITIES & TRENDS

  • 8.1 R&D OF GENITAL HERPES VACCINE CANDIDATES
  • 8.2 RISE IN GENITAL HERPES CASES IN LGBTQ+ COMMUNITY
  • 8.3 MARKET GROWTH POTENTIAL IN LOW-MIDDLE-INCOME COUNTRIES
  • 8.4 INCREASED ONLINE PURCHASE OF GENITAL HERPES THERAPEUTICS

9 MARKET GROWTH ENABLERS

  • 9.1 INCREASED BURDEN OF STDS
  • 9.2 AWARENESS OF STIS
  • 9.3 DEMAND FOR TOPICAL GENITAL HERPES TREATMENT DRUGS

10 MARKET RESTRAINTS

  • 10.1 SOCIAL STIGMA ASSOCIATED WITH STDS
  • 10.2 SIDE EFFECTS & ADVERSE REACTIONS TO GENITAL HERPES MEDICATIONS
    • 10.2.1 RISKS ASSOCIATED WITH VALACYCLOVIR
  • 10.3 LIMITATIONS OF GENITAL HERPES TREATMENT MEDICATIONS

11 MARKET LANDSCAPE

  • 11.1 MARKET OVERVIEW
  • 11.2 MARKET SIZE & FORECAST
  • 11.3 FIVE FORCES ANALYSIS
    • 11.3.1 THREAT OF NEW ENTRANTS
    • 11.3.2 BARGAINING POWER OF SUPPLIERS
    • 11.3.3 BARGAINING POWER OF BUYERS
    • 11.3.4 THREAT OF SUBSTITUTES
    • 11.3.5 COMPETITIVE RIVALRY

12 DRUG TYPE

  • 12.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 12.2 MARKET OVERVIEW
  • 12.3 ACYCLOVIR
    • 12.3.1 MARKET OVERVIEW
    • 12.3.2 MARKET SIZE & FORECAST
    • 12.3.3 ACYCLOVIR: GEOGRAPHY SEGMENTATION
  • 12.4 VALACYCLOVIR
    • 12.4.1 MARKET OVERVIEW
    • 12.4.2 MARKET SIZE & FORECAST
    • 12.4.3 VALACYCLOVIR: GEOGRAPHY SEGMENTATION
  • 12.5 FAMCICLOVIR
    • 12.5.1 MARKET OVERVIEW
    • 12.5.2 MARKET SIZE & FORECAST
    • 12.5.3 FAMCICLOVIR: GEOGRAPHY SEGMENTATION
  • 12.6 OTHER DRUGS
    • 12.6.1 MARKET OVERVIEW
    • 12.6.2 MARKET SIZE & FORECAST
    • 12.6.3 OTHER DRUGS: GEOGRAPHY SEGMENTATION

13 DISTRIBUTION CHANNEL

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 RETAIL PHARMACIES
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
    • 13.3.3 RETAIL PHARMACIES: GEOGRAPHY SEGMENTATION
  • 13.4 HOSPITAL PHARMACIES
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
    • 13.4.3 HOSPITAL PHARMACIES: GEOGRAPHY SEGMENTATION
  • 13.5 ONLINE PHARMACIES
    • 13.5.1 MARKET OVERVIEW
    • 13.5.2 MARKET SIZE & FORECAST
    • 13.5.3 ONLINE PHARMACIES: GEOGRAPHY SEGMENTATION

14 VIRUS TYPE

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 HSV-2
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
    • 14.3.3 HSV-2: GEOGRAPHY SEGMENTATION
  • 14.4 HSV-1
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
    • 14.4.3 HSV-1: GEOGRAPHY SEGMENTATION

15 ROUTE OF ADMINISTRATION

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW
  • 15.3 ORAL
    • 15.3.1 MARKET OVERVIEW
    • 15.3.2 MARKET SIZE & FORECAST
    • 15.3.3 ORAL: GEOGRAPHY SEGMENTATION
  • 15.4 TOPICAL
    • 15.4.1 MARKET OVERVIEW
    • 15.4.2 MARKET SIZE & FORECAST
    • 15.4.3 TOPICAL: GEOGRAPHY SEGMENTATION
  • 15.5 INJECTION
    • 15.5.1 MARKET OVERVIEW
    • 15.5.2 MARKET SIZE & FORECAST
    • 15.5.3 INJECTION: GEOGRAPHY SEGMENTATION

16 GEOGRAPHY

  • 16.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 16.2 GEOGRAPHIC OVERVIEW

17 NORTH AMERICA

  • 17.1 MARKET OVERVIEW
  • 17.2 MARKET SIZE & FORECAST
    • 17.2.1 NORTH AMERICA: DRUG TYPE SEGMENTATION
    • 17.2.2 NORTH AMERICA: DISTRIBUTION CHANNEL SEGMENTATION
    • 17.2.3 NORTH AMERICA: VIRUS TYPE SEGMENTATION
    • 17.2.4 NORTH AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
  • 17.3 KEY COUNTRIES
    • 17.3.1 US: MARKET SIZE & FORECAST
    • 17.3.2 CANADA: MARKET SIZE & FORECAST

18 EUROPE

  • 18.1 MARKET OVERVIEW
  • 18.2 MARKET SIZE & FORECAST
    • 18.2.1 EUROPE: DRUG TYPE SEGMENTATION
    • 18.2.2 EUROPE: DISTRIBUTION CHANNEL SEGMENTATION
    • 18.2.3 EUROPE: VIRUS TYPE SEGMENTATION
    • 18.2.4 EUROPE: ROUTE OF ADMINISTRATION SEGMENTATION
  • 18.3 KEY COUNTRIES
    • 18.3.1 GERMANY: MARKET SIZE & FORECAST
    • 18.3.2 FRANCE: MARKET SIZE & FORECAST
    • 18.3.3 UK: MARKET SIZE & FORECAST
    • 18.3.4 ITALY: MARKET SIZE & FORECAST
    • 18.3.5 SPAIN: MARKET SIZE & FORECAST

19 APAC

  • 19.1 MARKET OVERVIEW
  • 19.2 MARKET SIZE & FORECAST
    • 19.2.1 APAC: DRUG TYPE SEGMENTATION
    • 19.2.2 APAC: DISTRIBUTION CHANNEL SEGMENTATION
    • 19.2.3 APAC: VIRUS TYPE SEGMENTATION
    • 19.2.4 APAC: ROUTE OF ADMINISTRATION SEGMENTATION
  • 19.3 KEY COUNTRIES
    • 19.3.1 CHINA: MARKET SIZE & FORECAST
    • 19.3.2 JAPAN: MARKET SIZE & FORECAST
    • 19.3.3 INDIA: MARKET SIZE & FORECAST
    • 19.3.4 SOUTH KOREA: MARKET SIZE & FORECAST
    • 19.3.5 AUSTRALIA: MARKET SIZE & FORECAST

20 LATIN AMERICA

  • 20.1 MARKET OVERVIEW
  • 20.2 MARKET SIZE & FORECAST
    • 20.2.1 LATIN AMERICA: DRUG TYPE SEGMENTATION
    • 20.2.2 LATIN AMERICA: DISTRIBUTION CHANNEL SEGMENTATION
    • 20.2.3 LATIN AMERICA: VIRUS TYPE SEGMENTATION
    • 20.2.4 LATIN AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
  • 20.3 KEY COUNTRIES
    • 20.3.1 BRAZIL: MARKET SIZE & FORECAST
    • 20.3.2 MEXICO: MARKET SIZE & FORECAST
    • 20.3.3 ARGENTINA: MARKET SIZE & FORECAST

21 MIDDLE EAST & AFRICA

  • 21.1 MARKET OVERVIEW
  • 21.2 MARKET SIZE & FORECAST
    • 21.2.1 MEA: DRUG TYPE SEGMENTATION
    • 21.2.2 MEA: DISTRIBUTION CHANNEL SEGMENTATION
    • 21.2.3 MEA: VIRUS TYPE SEGMENTATION
    • 21.2.4 MEA: ROUTE OF ADMINISTRATION SEGMENTATION
  • 21.3 KEY COUNTRIES
    • 21.3.1 SOUTH AFRICA: MARKET SIZE & FORECAST
    • 21.3.2 TURKEY: MARKET SIZE & FORECAST
    • 21.3.3 SAUDI ARABIA: MARKET SIZE & FORECAST

22 COMPETITIVE LANDSCAPE

  • 22.1 COMPETITION OVERVIEW
  • 22.2 MARKET SHARE ANALYSIS

23 KEY COMPANY PROFILES

  • 23.1 GLAXOSMITHKLINE
    • 23.1.1 BUSINESS OVERVIEW
    • 23.1.2 GLAXOSMITHKLINE IN GLOBAL GENITAL HERPES TREATMENT MARKET
    • 23.1.3 PRODUCT OFFERINGS
    • 23.1.4 KEY STRATEGIES
    • 23.1.5 KEY STRENGTHS
    • 23.1.6 KEY OPPORTUNITIES
  • 23.2 GLENMARK PHARMACEUTICALS
    • 23.2.1 BUSINESS OVERVIEW
    • 23.2.2 GLENMARK PHARMACEUTICALS IN GLOBAL GENITAL HERPES TREATMENT MARKET
    • 23.2.3 PRODUCT OFFERINGS
    • 23.2.4 KEY STRATEGIES
    • 23.2.5 KEY STRENGTHS
    • 23.2.6 KEY OPPORTUNITIES
  • 23.3 VIATRIS
    • 23.3.1 BUSINESS OVERVIEW
    • 23.3.2 VIATRIS IN GLOBAL GENITAL HERPES TREATMENT MARKET
    • 23.3.3 PRODUCT OFFERINGS
    • 23.3.4 KEY STRATEGIES
    • 23.3.5 KEY STRENGTHS
    • 23.3.6 KEY OPPORTUNITY
  • 23.4 NOVARTIS AG
    • 23.4.1 BUSINESS OVERVIEW
    • 23.4.2 NOVARTIS AG IN GLOBAL GENITAL HERPES TREATMENT MARKET
    • 23.4.3 PRODUCT OFFERINGS
    • 23.4.4 KEY STRATEGIES
    • 23.4.5 KEY STRENGTHS
    • 23.4.6 KEY OPPORTUNITIES
  • 23.5 TEVA PHARMACEUTICALS
    • 23.5.1 BUSINESS OVERVIEW
    • 23.5.2 TEVA PHARMACEUTICALS IN GLOBAL GENITAL HERPES TREATMENT MARKET
    • 23.5.3 PRODUCT OFFERINGS
    • 23.5.4 KEY STRATEGIES
    • 23.5.5 KEY STRENGTHS
    • 23.5.6 KEY OPPORTUNITIES
  • 23.6 BAUSCH HEALTH COMPANIES INC.
    • 23.6.1 BUSINESS OVERVIEW
    • 23.6.2 BAUSCH HEALTH COMPANIES INC. IN GLOBAL GENITAL HERPES TREATMENT MARKET
    • 23.6.3 PRODUCT OFFERINGS
    • 23.6.4 KEY STRATEGIES
    • 23.6.5 KEY STRENGTHS
    • 23.6.6 KEY OPPORTUNITIES

24 OTHER PROMINENT VENDORS

  • 24.1 AVET PHARMACEUTICALS
    • 24.1.1 BUSINESS OVERVIEW
    • 24.1.2 PRODUCT OFFERINGS
  • 24.2 AUROBINDO PHARMA
    • 24.2.1 BUSINESS OVERVIEW
    • 24.2.2 PRODUCT OFFERINGS
  • 24.3 ABBOTT
    • 24.3.1 BUSINESS OVERVIEW
    • 24.3.2 PRODUCT OFFERINGS
  • 24.4 ADLEY FORMULATIONS
    • 24.4.1 BUSINESS OVERVIEW
    • 24.4.2 PRODUCT OFFERINGS
  • 24.5 CENTURION REMEDIES
    • 24.5.1 BUSINESS OVERVIEW
    • 24.5.2 PRODUCT OFFERINGS
  • 24.6 CIPLA
    • 24.6.1 BUSINESS OVERVIEW
    • 24.6.2 PRODUCT OFFERINGS
  • 24.7 DR. REDDY'S LABORATORIES
    • 24.7.1 BUSINESS OVERVIEW
    • 24.7.2 PRODUCT OFFERINGS
  • 24.8 ELI LILLY AND COMPANY
    • 24.8.1 BUSINESS OVERVIEW
    • 24.8.2 PRODUCT OFFERINGS
  • 24.9 FDC LIMITED
    • 24.9.1 BUSINESS OVERVIEW
    • 24.9.2 PRODUCT OFFERINGS
  • 24.10 FINECURE PHARMACEUTICALS LIMITED
    • 24.10.1 BUSINESS OVERVIEW
    • 24.10.2 PRODUCT OFFERINGS
  • 24.11 HETERO
    • 24.11.1 BUSINESS OVERVIEW
    • 24.11.2 PRODUCT OFFERINGS
  • 24.12 MACLEODS PHARMACEUTICALS
    • 24.12.1 BUSINESS OVERVIEW
    • 24.12.2 PRODUCT OFFERINGS
  • 24.13 MEDICO REMEDIES LIMITED
    • 24.13.1 BUSINESS OVERVIEW
    • 24.13.2 PRODUCT OFFERINGS
  • 24.14 PFIZER INC.
    • 24.14.1 BUSINESS OVERVIEW
    • 24.14.2 PRODUCT OFFERINGS
  • 24.15 TORRENT PHARMA
    • 24.15.1 BUSINESS OVERVIEW
    • 24.15.2 PRODUCT OFFERINGS
  • 24.16 ZEELAB PHARMACY
    • 24.16.1 BUSINESS OVERVIEW
    • 24.16.2 PRODUCT OFFERINGS
  • 24.17 ZYDUS GROUP
    • 24.17.1 BUSINESS OVERVIEW
    • 24.17.2 PRODUCT OFFERINGS

25 REPORT SUMMARY

  • 25.1 KEY TAKEAWAYS
  • 25.2 STRATEGIC RECOMMENDATIONS

26 QUANTITATIVE SUMMARY

  • 26.1 DRUG TYPE
    • 26.1.1 NORTH AMERICA: DRUG TYPE SEGMENTATION
    • 26.1.2 EUROPE: DRUG TYPE SEGMENTATION
    • 26.1.3 APAC: DRUG TYPE SEGMENTATION
    • 26.1.4 LATIN AMERICA: DRUG TYPE SEGMENTATION
    • 26.1.5 MIDDLE EAST & AFRICA: DRUG TYPE SEGMENTATION
  • 26.2 DISTRIBUTION CHANNEL
    • 26.2.1 NORTH AMERICA: DISTRIBUTION CHANNEL
    • 26.2.2 EUROPE: DISTRIBUTION CHANNEL
    • 26.2.3 APAC: DISTRIBUTION CHANNEL
    • 26.2.4 LATIN AMERICA: DISTRIBUTION CHANNEL
    • 26.2.5 MIDDLE EAST & AFRICA: DISTRIBUTION CHANNEL
  • 26.3 VIRUS TYPE
    • 26.3.1 NORTH AMERICA: VIRUS TYPE SEGMENTATION
    • 26.3.2 EUROPE: VIRUS TYPE SEGMENTATION
    • 26.3.3 APAC: VIRUS TYPE SEGMENTATION
    • 26.3.4 LATIN AMERICA: VIRUS TYPE SEGMENTATION
    • 26.3.5 MIDDLE EAST & AFRICA: VIRUS TYPE SEGMENTATION
  • 26.4 ROUTE OF ADMINISTRATION
    • 26.4.1 NORTH AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
    • 26.4.2 EUROPE: ROUTE OF ADMINISTRATION SEGMENTATION
    • 26.4.3 APAC: ROUTE OF ADMINISTRATION SEGMENTATION
    • 26.4.4 LATIN AMERICA: ROUTE OF ADMINISTRATION SEGMENTATION
    • 26.4.5 MIDDLE EAST & AFRICA: ROUTE OF ADMINISTRATION SEGMENTATION
  • 26.5 GEOGRAPHY
    • 26.5.1 ACYCLOVIR: GEOGRAPHY SEGMENTATION
    • 26.5.2 VALACYCLOVIR: GEOGRAPHY SEGMENTATION
    • 26.5.3 FAMCICLOVIR: GEOGRAPHY SEGMENTATION
    • 26.5.4 OTHER DRUGS: GEOGRAPHY SEGMENTATION
    • 26.5.5 RETAIL PHARMACIES: GEOGRAPHY SEGMENTATION
    • 26.5.6 HOSPITAL PHARMACIES: GEOGRAPHY SEGMENTATION
    • 26.5.7 ONLINE PHARMACIES: GEOGRAPHY SEGMENTATION
    • 26.5.8 HSV-2: GEOGRAPHY SEGMENTATION
    • 26.5.9 HSV-1: GEOGRAPHY SEGMENTATION
    • 26.5.10 ORAL: GEOGRAPHY SEGMENTATION
    • 26.5.11 TOPICAL: GEOGRAPHY SEGMENTATION
    • 26.5.12 INJECTION: GEOGRAPHY SEGMENTATION

27 APPENDIX

  • 27.1 ABBREVIATIONS